As of November 15, 2026, Kiniksa Pharmaceuticals International, plc has reported one exit or restructuring plan to the SEC on Form 8-K under Item 2.05, the latest filed on February 25, 2025. No WARN notice under its name is on file in the states covered here (Form 8-K, February 25, 2025).
10 companies announced layoffs this week, 1 had other signals.
Companies cutting jobs this week. Before you unlock: the company, the number of employees and what is inside. After: every way we found to reach the company. No individual is named in a layoff.
| UPWORK, INC | announced layoffs | |
| PVH CORP. /DE/ | announced layoffs | |
| Battelle | filed a layoff notice for 15 employees | |
| TidalHealth Primary Care | filed a layoff notice for 5 employees | |
| Phunware, Inc. | announced layoffs |
Is this your company?
Owed money by them or selling to them? See the free Snapshot of Kiniksa Pharmaceuticals International, plc.
Free to see. No signup.
People from Kiniksa Pharmaceuticals International, plc who say they are open to work
Only people who added themselves are listed here. Nobody is named because of a company announcement or a news story, and we have not checked what anyone says about themselves.
Loading the list…
Affected by the Kiniksa Pharmaceuticals International, plc layoff? Add yourself to the open-to-work list, free
Your entry
Kiniksa Pharmaceuticals International, plc reported 1 exit or restructuring plan on Form 8-K under Item 2.05. Each fact below is the filing's own sentence, quoted and linked. No WARN notice under this company's name is on file in the states covered here.
Did Kiniksa Pharmaceuticals International have layoffs in 2025? What its filings say
Kiniksa Pharmaceuticals International, plc (CIK 1730430) reported 1 exit or restructuring plan to the SEC on Form 8-K under Item 2.05. The sentences below are quoted from the filings as written.
Form 8-K filed 2025-02-25
Expected charges
As a result of the termination of the Phase 2b clinical trial, the Company has incurred approximately $19 million in expenses and expects to record approximately $14 million to $17 million in additional expenses, almost entirely consisting of expenses related to contract termination costs for the Company's clinical supply agreements for abiprubart, with additional de minimis costs related to trial closeout activities.
Timing
The Company expects to immediately end enrollment and initiate winddown activities for the clinical trial, with full completion of winddown activities expected to occur by the end of 2025.
Also on the record for Kiniksa Pharmaceuticals International, plc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 22, 2026 | Leadership change: Ross Moat appointed, Chief Operating Officer | — | Leadership changes | Source |
| July 29, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.5% of the class | 5%+ stakes | Source |
| May 26, 2026 | Stake report, Schedule 13D/A, by Baker Bros. Advisors LP | 7% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 14.8% of the class | 5%+ stakes | Source |
| May 1, 2026 | Leadership change: Eben Tessari departs, Chief Strategy Officer, and 1 more | — | Leadership changes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| March 6, 2026 | Stake report, Schedule 13G, by FMR LLC | 10.6% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Rubric Capital Management LP | 7.37% of the class | 5%+ stakes | Source |
| January 14, 2026 | Leadership change: Ross Moat appointed, Chief Operating Officer, and 1 more | — | Leadership changes | Source |
| October 31, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 7.04% of the class | 5%+ stakes | Source |
| July 17, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 1% of the class | 5%+ stakes | Source |
| July 9, 2025 | Stake report, Schedule 13G/A, by RUBRIC CAPITAL MANAGEMENT LP | 9.24% of the class | 5%+ stakes | Source |
Keep reading
More on Kiniksa Pharmaceuticals International, plc and the records around it.
Kiniksa Pharmaceuticals International, plc elsewhere on the record
- 5%+ stake filings Jul 2026
- Leadership changes May 2026
- Who owns it
Companies that share a holder
- Baker Bros. Advisors LP also filed stake reports on 25 other companies: Madrigal Pharmaceuticals, Inc. (Nov 2026), Kodiak Sciences Inc. (Sep 2026), BeOne Medicines Ltd. (Sep 2026)
- Rubric Capital Management LP also filed stake reports on 32 other companies: ARDELYX, INC. (Aug 2026), Enovis Corporation (Aug 2026), MeiraGTx Holdings plc (Aug 2026)
- FMR LLC also filed stake reports on 762 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Watch Kiniksa Pharmaceuticals International, plc
Get an email when Kiniksa Pharmaceuticals International, plc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
What do you want to do with Kiniksa Pharmaceuticals International, plc?
Want the whole picture on Kiniksa Pharmaceuticals International, plc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Kiniksa Pharmaceuticals International, plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Kiniksa Pharmaceuticals International, plc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Tools for this story
Each opens in a new tab, filled in for Kiniksa Pharmaceuticals International, plc. With no account yet, you sign up free and land on the result.
Public companies must also report to the SEC, on Form 8-K under Item 2.05, when they commit to an exit or restructuring plan that will cost them material charges, which is how most large layoffs and closures by listed companies are disclosed. Those filings are national, so they cover companies in every state. Each sentence shown from one is quoted exactly and linked to the filing; where a filing does not state a figure, none is shown.
Where this comes from
Employers covered by the federal WARN Act, and by the stricter laws some states add, must give written notice before a mass layoff or a site closure. The state labor department publishes those notices. Every row here is one of them, taken from that state's own published file and linked to it, so each figure can be checked at the source.
A notice states the employer, the location, the number of employees affected, and when the layoff or closure takes effect. It does not state a reason, and neither does this page. Where a company also appears in SEC filings under the same name and in the same state, its recorded fundraising is shown alongside, as a matter of record rather than as an explanation. New Jersey and Pennsylvania list a notice under the month it was posted or received, not the day, so their notices show a month. Tennessee gives the county rather than the city.
Related
- Metropolis Company: 140 jobs, Jan 2025 layoff notice within 90 days (2025-01-22)
- Rapid Reliable Care by DocGo, LLC: 382 jobs, Mar 2025 layoff notice within 90 days (2025-03-25)
- Catholic Charities of Orange, Sullivan & Ulster: 4 WARN notices, 30 employees, Feb 2025 layoff notice within 90 days (2025-02-19)
- Repare Therapeutics Inc.: 2 SEC filings, Feb 2025 layoff notice within 90 days (2025-02-25)
- Eagle Healthcare LLC: 250 jobs, May 2025 layoff notice within 90 days (2025-05-19)
- Fortune Brands Innovations, Inc.: 1 SEC filing, Jan 2025 layoff notice within 90 days (2025-01-22)
Who owns Kiniksa Pharmaceuticals International, plc? Owners, funding and legal record
Cite this page
https://mentionfox.com/layoffs/kiniksa-pharmaceuticals-international